SG10201606301YA - Novel imidazole amines as modulators of kinase activity - Google Patents

Novel imidazole amines as modulators of kinase activity

Info

Publication number
SG10201606301YA
SG10201606301YA SG10201606301YA SG10201606301YA SG10201606301YA SG 10201606301Y A SG10201606301Y A SG 10201606301YA SG 10201606301Y A SG10201606301Y A SG 10201606301YA SG 10201606301Y A SG10201606301Y A SG 10201606301YA SG 10201606301Y A SG10201606301Y A SG 10201606301YA
Authority
SG
Singapore
Prior art keywords
modulators
kinase activity
novel imidazole
imidazole amines
amines
Prior art date
Application number
SG10201606301YA
Other languages
English (en)
Inventor
Ruoxi Lan
Bayard R Huck
Xiaoling Chen
Yufang Xiao
Lizbeth Celeste Deselm
Hui Qiu
Constantin Neagu
Donald Bankston
Christopher Charles Victor Jones
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG10201606301YA publication Critical patent/SG10201606301YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG10201606301YA 2011-09-12 2012-09-12 Novel imidazole amines as modulators of kinase activity SG10201606301YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161533601P 2011-09-12 2011-09-12

Publications (1)

Publication Number Publication Date
SG10201606301YA true SG10201606301YA (en) 2016-09-29

Family

ID=46881179

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2014009278A SG2014009278A (en) 2011-09-12 2012-09-12 Novel imidazole amines as modulators of kinase activity
SG10201606301YA SG10201606301YA (en) 2011-09-12 2012-09-12 Novel imidazole amines as modulators of kinase activity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2014009278A SG2014009278A (en) 2011-09-12 2012-09-12 Novel imidazole amines as modulators of kinase activity

Country Status (25)

Country Link
US (2) US9145392B2 (zh)
EP (1) EP2755965B1 (zh)
JP (1) JP5964974B2 (zh)
KR (1) KR101995605B1 (zh)
CN (1) CN104080782B (zh)
AU (1) AU2012308696B2 (zh)
BR (1) BR112014005554A2 (zh)
CA (1) CA2844830C (zh)
DK (1) DK2755965T3 (zh)
EA (1) EA025098B1 (zh)
ES (1) ES2644536T3 (zh)
HK (1) HK1201825A1 (zh)
HR (1) HRP20171554T1 (zh)
HU (1) HUE035019T2 (zh)
IL (1) IL231383A (zh)
LT (1) LT2755965T (zh)
MX (1) MX346095B (zh)
NO (1) NO2791461T3 (zh)
PL (1) PL2755965T3 (zh)
PT (1) PT2755965T (zh)
RS (1) RS56534B1 (zh)
SG (2) SG2014009278A (zh)
SI (1) SI2755965T1 (zh)
WO (1) WO2013040059A1 (zh)
ZA (1) ZA201401013B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2755958T1 (sl) * 2011-09-12 2017-12-29 Merck Patent Gmbh Aminopirimidinski derivati za uporabo kot modulatorji kinazne aktivnosti
GEP201706623B (en) 2012-10-16 2017-02-10 Almirall Sa Pyrrolotriazinone derivatives as pi3k inhibitors
CN105102435A (zh) 2012-11-16 2015-11-25 默克专利有限公司 用作激酶活性调节剂的新颖的咪唑-哌啶基衍生物
KR20150124957A (ko) * 2013-03-11 2015-11-06 메르크 파텐트 게엠베하 키나아제 활성의 조절인자로서 (6-[4-1h-이미다졸-2-일)피페리딘-1-일]피리미딘-4-아민 유도체
BR112016015285A8 (pt) * 2014-02-11 2020-06-09 Merck Patent Gmbh pirimidina imidazol aminas como moduladores da atividade de quinase, seus usos e seu processo de preparação, composição farmacêutica, e kit
WO2015159938A1 (ja) 2014-04-18 2015-10-22 武田薬品工業株式会社 複素環化合物
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药(上海)有限公司 环烯烃取代的杂芳环类化合物及其用途
KR20200093159A (ko) 2019-01-28 2020-08-05 주식회사 링크모션 스마트 팜 모듈 구조물
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
US11866421B2 (en) 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
PE20241335A1 (es) 2021-06-04 2024-07-03 Vertex Pharma N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
CN117567435A (zh) * 2022-01-30 2024-02-20 上海市第十人民医院 谷氨酰胺环化酶抑制剂及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
EP1615906A1 (en) 2003-04-03 2006-01-18 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
WO2005033086A1 (en) 2003-09-30 2005-04-14 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1678168B1 (en) 2003-10-24 2012-07-11 Exelixis, Inc. P70s6 kinase modulators and method of use
AU2004295061B2 (en) 2003-11-21 2008-11-20 Novartis Ag 1H-imidazoquinoline derivatives as protein kinase inhibitors
CN1889958A (zh) 2003-12-09 2007-01-03 美国政府健康及人类服务部 抑制免疫应答或治疗增生性疾病的方法
CA2563699C (en) 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス, インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター(p70S6K、Akt−1およびAkt−2)としての[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジンまたは[1H−ピペラゾ[3,4−d]ピリミジン−4−イル]−ピペラジン化合物
JP2008528506A (ja) * 2005-01-19 2008-07-31 ニューロジェン・コーポレーション ヘテロアリール置換ピペラジニル−ピリジン類縁体
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
JP2008546751A (ja) 2005-06-22 2008-12-25 アステックス・セラピューティクス・リミテッド 医薬組成物
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
EA020731B1 (ru) 2009-02-11 2015-01-30 Мерк Патент Гмбх Аминоазагетероциклические карбоксамиды
CN103140484B (zh) 2010-07-29 2015-04-22 默克专利有限公司 环状胺氮杂杂环甲酰胺
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
KR101894116B1 (ko) 2010-11-24 2018-08-31 메르크 파텐트 게엠베하 퀴나졸린 카르복사미드 아제티딘

Also Published As

Publication number Publication date
EA025098B1 (ru) 2016-11-30
CN104080782B (zh) 2016-06-01
MX346095B (es) 2017-03-07
KR20140063694A (ko) 2014-05-27
MX2014002832A (es) 2014-05-27
US20140343029A1 (en) 2014-11-20
EP2755965B1 (en) 2017-07-26
DK2755965T3 (en) 2017-09-25
JP5964974B2 (ja) 2016-08-03
KR101995605B1 (ko) 2019-07-02
AU2012308696B2 (en) 2017-04-27
HRP20171554T1 (hr) 2017-11-17
HUE035019T2 (en) 2018-03-28
CA2844830A1 (en) 2013-03-21
LT2755965T (lt) 2017-11-10
ZA201401013B (en) 2018-07-25
WO2013040059A1 (en) 2013-03-21
HK1201825A1 (zh) 2015-09-11
AU2012308696A1 (en) 2014-02-27
US20160000785A1 (en) 2016-01-07
IL231383A (en) 2017-11-30
EP2755965A1 (en) 2014-07-23
BR112014005554A2 (pt) 2017-03-21
EA201400339A1 (ru) 2014-08-29
CN104080782A (zh) 2014-10-01
ES2644536T3 (es) 2017-11-29
US9145392B2 (en) 2015-09-29
PL2755965T3 (pl) 2018-01-31
SI2755965T1 (sl) 2017-12-29
NO2791461T3 (zh) 2018-07-21
CA2844830C (en) 2019-09-10
PT2755965T (pt) 2017-11-02
JP2014531436A (ja) 2014-11-27
SG2014009278A (en) 2014-07-30
IL231383A0 (en) 2014-04-30
RS56534B1 (sr) 2018-02-28

Similar Documents

Publication Publication Date Title
HRP20190128T1 (hr) Novi spojevi kao modulatori protein kinaza
HK1201825A1 (zh) 用作激酶活性調節劑的咪唑胺
ZA201401007B (en) Aminopyrimidine derivative for use as modulators of kinase activity
EP2783284A4 (en) SYSTEM FOR QUALITY IMPROVEMENT OF DISTRIBUTED SOFTWARE
IL228103A0 (en) Amino-quinolines as kinase inhibitors
IL228945A0 (en) Modified bicyclylmethylamine derivatives as sphingosine-1-phosphate receptor modulators
EP2685992A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
EP2836479A4 (en) USE OF NEW AMINES FOR STABILIZING QUATERNARY TRIALKYLALCANOLAMINES
PL2753330T3 (pl) Terapeutyczne zastosowania ektoiny
HK1201829A1 (zh) 用作激酶活性調節劑的新穎的雜環羧酰胺
IL243729B (en) Novel h4–chromin–4–one compounds as novel protein kinase modulators
GB2494923B (en) Set of support assemblies